ATOSSA GENETICS INC
NASDAQ: ATOS (Atossa Therapeutics, Inc.)
最近更新时间: 昨天, 6:29AM0.763
0.01 (1.17%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Atossa Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.38 |
|
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.07% |
| 机构持股比例 | 26.58% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 30 Jun 2025 | 386,334 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 7.50 (Ascendiant Capital, 883.09%) | 购买 |
| 中 | 5.75 (653.70%) | |
| 低 | 4.00 (Craig-Hallum, 424.32%) | 购买 |
| 平均值 | 5.75 (653.70%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 0.880 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Ascendiant Capital | 06 Jun 2025 | 7.50 (883.09%) | 购买 | 0.900 |
| Craig-Hallum | 05 Jun 2025 | 4.00 (424.32%) | 购买 | 0.860 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合